APSR2026-633

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-020
P20
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1252973-46904-APSR2026-633_441013.pdf
Format: PDF Only
07. COPD
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Norsyazwan Salim Lim - Hospital Kepala Batas Pharmacy Kepala Batas Malaysia
Afidah Abdul Aziz - Seberang Perai Utara District Health Office Pharmacy Seberang Perai Utara Malaysia
Phin Phin Lim - Penang State Health Department 3Pharmaceutical Service Division Georgetown Malaysia
Jaya Muneswarao * Hospital Pulau Pinang Pharmacy Georgetown Malaysia
Subramaniam Thanimalai - Hospital Sultanah Bahiyah Pharmacy Alor Setar Malaysia
Irfhan Ali Hyder Ali - Hospital Pulau Pinang Respiratory Georgetown Malaysia
Lalitha Pereirasamy - Hospital Pulau Pinang Respiratory Georgetown Malaysia
 
 
 
 
 
 
 
 
Presenting Author Details
Jaya Muneswarao
Ramadoo
rahulraoraorao@gmail.com
+60122239848
31-40
Malaysia
Original Research
Assessing the budget impact of incorporating single inhaler triple therapy as treatment option for moderate to very severe COPD patients in tertiary hospitals in Penang
Maximum 25 words
Abstract Content
Triple therapy for Chronic Obstructive Pulmonary Disease (COPD) combines an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). The current triple therapy available in Penang state government hospitals involves Multiple Inhaler Triple Therapy (MITT). A new Single Inhaler Triple Therapy (SITT), Budesonide/Glycopyrronium/Formoterol, is expected to improve patient adherence and clinical outcomes. However, its affordability requires thorough evaluation. This study aimed to assess the budget impact of introducing SITT in moderate to very severe COPD patients with blood eosinophil >300 cells/microlitre (with history of exacerbation) from the perspective of the budget provider over a 3-year time horizon.
This study focused on eligible patients receiving treatment in Hospital Pulau Pinang (HPP) and Hospital Seberang Jaya (HSJ). An Excel-based cost calculator was developed to compare the total costs of the current treatment mix consisting of two treatment options (LAMA/LABA and MITT) versus a future treatment mix (LAMA/LABA, MITT and SITT). Costs related to drugs and clinical events were based on published studies, official tariffs, databases and expert opinion.
The gradual introduction of SITT up to 50% of the target population by Year 3 was associated with a total incremental cost of RM 281,758.86 (11.74%). The total drug acquisition cost after SITT increased by RM388,135.64 over three years, whereas the disease-related cost decreased by RM106,376.78 due to the lower exacerbation rate in SITT. Sensitivity analyses on drug acquisition cost revealed that cost savings (RM42,183.29) over three years could be achieved with a 35% reduction in current SITT cost (RM165.80/device), assuming no change in other variables.
The adoption of SITT in 50% of the target population required an incremental cost. Cost savings can be achieved with lower SITT cost, provided other variables remain constant.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Budget impact analysis, Single inhaler triple therapy, Chronic obstructive pulmonary disease
maximum 3 keywords and no abbreviations, separated by commas
 
300